Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_4
1
33%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 4Post-market surveillance
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Other(2)

Detailed Status

unknown2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (50.0%)
N/A1 (50.0%)

Trials by Status

unknown267%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_4

Adenomyosis and ART

NCT05937490
completed

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

NCT02993926
unknownnot_applicable

Comparison of a Novel Leuprolide With Market Leuprolide

NCT03662958

Clinical Trials (3)

Showing 3 of 3 trials
NCT05937490Phase 4

Adenomyosis and ART

Unknown
NCT02993926

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Completed
NCT03662958Not Applicable

Comparison of a Novel Leuprolide With Market Leuprolide

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3